MASAN : a novel staging system for prognosis of patients with oesophageal squamous cell carcinoma
Menée sur 77 patients atteints d'un carcinome épidermoïde de l'œsophage puis validée sur 77 et 150 patients complémentaires, cette étude évalue la performance d'un nouveau système, basé sur des facteurs clinico-pathologiques (âge, stade N) et l'expression de marqueurs moléculaires (MYC, ANO1 et SLC52A3), pour établir un pronostic
Background : Oesophageal squamous cell carcinoma (ESCC) is one of the most malignant cancers worldwide. Treatment of ESCC is in progress through accurate staging and risk assessment of patients. The emergence of potential molecular markers inspired us to construct novel staging systems with better accuracy by incorporating molecular markers.
Methods : We measured H scores of 23 protein markers and analysed eight clinical factors of 77 ESCC patients in a training set, from which we identified an optimal MASAN (MYC, ANO1, SLC52A3, Age and N-stage) signature. We constructed MASAN models using Cox PH models, and created MASAN-staging systems based on k-means clustering and minimum-distance classifier. MASAN was validated in a test set (n = 77) and an independent validation set (n = 150).
Results : MASAN possessed high predictive accuracies and stratified ESCC patients into three prognostic groups that were more accurate than the current pTNM-staging system for both overall survival and disease-free survival. To facilitate clinical utilisation, we also constructed MASAN-SI staging systems based on staining indices (SI) of protein markers, which possessed similar prognostic performance as MASAN.
Conclusion : MASAN provides a good alternative staging system for ESCC prognosis with a high precision using a simple model.
British Journal of Cancer , résumé, 2018